SARS‐CoV‐2 infection and vaccination in patients with hairy‐cell leukaemia. (20th December 2022)

• Record Type: Journal Article
• Authors: Tiacci, Enrico; Mancini, Alessandro; Marchetti, Monia; D'Elia, Gianna Maria; Candoni, Anna; Morotti, Alessandro; Romano, Alessandra; Gozzetti, Alessandro; Broccoli, Alessandro; De Carolis, Luca; Bruna, Riccardo; Tisi, Maria Chiara; Selleri, Carmine; Capponi, Monia; Vallisa, Daniele; Cattaneo, Chiara; Della Porta, Matteo Giovanni; Busca, Alessandro; Falini, Brunangelo; Massaia, Massimo; Bertù, Lorenza; Pulsoni, Alessandro; Rivela, Paolo; Corradini, Paolo; Passamonti, Francesco
• Is Part Of: British journal of haematology. Volume 201:Number 3(2023)
• Page Start: 411
• Page End: 416
• Publication Date: 2022-12-20
• Subjects: anti‐SARS‐CoV‐2 vaccination -- COVID‐19 -- hairy‐cell leukaemia -- post‐COVID‐19 seroconversion; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.18606
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: Little is known of the course of COVID‐19 and the antibody response to infection or vaccination in patients with hairy‐cell leukaemia (HCL). Among a total of 58 HCL cases we studied in these regards, 37 unvaccinated patients, mostly enjoying a relatively long period free from anti‐leukaemic treatment, developed COVID‐19 between March 2020 and December 2021 with a usually favourable outcome (fatality rate: 5/37, 14%); however, active leukaemia, older age and more comorbidities were associated with a worse course. Postinfection ( n = 11 cases) and postvaccination ( n = 28) seroconversion consistently developed, except after recent anti‐CD20 or venetoclax therapy, correlating with perivaccine B‐cell count. Vaccination appeared to protect from severe COVID‐19 in 11 patients with breakthrough infection.